{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:36:52Z","timestamp":1760060212999,"version":"build-2065373602"},"reference-count":67,"publisher":"MDPI AG","issue":"15","license":[{"start":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T00:00:00Z","timestamp":1754438400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>T-cell-engaging antibodies are a promising new type of treatment for patients with refractory or relapsed (R\/R) diffuse large B-cell lymphoma, which has changed the prognosis and evolution of these patients in clinical trials. Bispecific antibodies (BsAbs) bind to two different targets (B and T lymphocytes) at the same time and in this way mimic the action of CAR (chimeric antigen receptor) T-cells. They are the T-cell-engaging antibodies most used in practice and are a solution for patients who do not respond to second- or later-line therapies, including chemoimmunotherapy, followed by salvage chemotherapy and hematopoietic stem cell transplantation. They are a therapeutic option for patients who are ineligible for CAR T-cell therapy and are also active in those with prior exposure to CAR T-cell treatment. A remarkable advantage of BsAbs is their rapid availability, even if the disease progresses rapidly, unlike CAR T-cell treatment, and they avoid the practical and financial challenges raised by autologous CAR T-cell therapies. CAR-T has been proven to have better efficacy compared to BsAbs, but cytokine release syndrome and neurotoxicity have appeared significantly more frequently in patients treated with CAR T-cells. The possibility of combining BsAbs with chemotherapy and their administration for relapses or as a frontline therapy is being studied to increase their efficacy. BsAbs are a life-saving therapy for many patients with diffuse large B-cell malignant non-Hodgkin\u2019s lymphoma (NHL) who have a poor prognosis with classical therapies, but are not without adverse effects and require careful monitoring.<\/jats:p>","DOI":"10.3390\/jcm14155534","type":"journal-article","created":{"date-parts":[[2025,8,6]],"date-time":"2025-08-06T10:13:51Z","timestamp":1754475231000},"page":"5534","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bispecific Antibodies\u2014A New Hope for Patients with Diffuse Large B-Cell Lymphoma"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9198-353X","authenticated-orcid":false,"given":"Romeo Gabriel","family":"Mihaila","sequence":"first","affiliation":[{"name":"Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550024 Sibiu, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samuel B.","family":"Todor","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, \u201cLucian Blaga\u201d University of Sibiu, 550024 Sibiu, Romania"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1053\/j.seminhematol.2023.11.001","article-title":"Antibody and Immunotherapy in Diffuse Large B-Cell Lymphoma","volume":"60","author":"Barraclough","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"D\u2019Al\u00f2, F., Bellesi, S., Maiolo, E., Alma, E., Bellisario, F., Malafronte, R., Viscovo, M., Campana, F., and Hohaus, S. (2024). Novel Targets and Advanced Therapies in Diffuse Large B Cell Lymphomas. Cancers, 16.","DOI":"10.3390\/cancers16122243"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"S2152265024001812","DOI":"10.1016\/j.clml.2024.05.010","article-title":"SOHO State of the Art Updates and Next Questions|Current Evidence and Future Directions for Bispecific Antibodies in Large B-Cell Lymphoma","volume":"24","author":"Bennett","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1080\/14712598.2024.2312243","article-title":"An Evaluation of Glofitamab, the First Fixed-Duration Bispecific Antibody for Relapsed or Refractory Large B-Cell Lymphomas","volume":"24","author":"Polgarova","year":"2024","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s40164-023-00432-z","article-title":"The Progress of Novel Strategies on Immune-Based Therapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"12","author":"Lu","year":"2023","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Saleh, K., Khoury, R., Khalife, N., Chahine, C., Ibrahim, R., Tikriti, Z., and Le Cesne, A. (2024). The Evolving Role of Bispecific Antibodies in Diffuse Large B-Cell Lymphoma. J. Pers. Med., 14.","DOI":"10.3390\/jpm14070666"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"e7448","DOI":"10.1002\/cam4.7448","article-title":"Real Life Clinical Outcomes of Relapsed\/Refractory Diffuse Large B Cell Lymphoma in the Rituximab Era: The STRIDER Study","volume":"13","author":"Dogliotti","year":"2024","journal-title":"Cancer Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1007\/s12185-024-03750-y","article-title":"Prognostic Model for Relapsed\/Refractory Transplant-Ineligible Diffuse Large B-Cell Lymphoma Utilizing the Lymphocyte-to-Monocyte Ratio","volume":"119","author":"Ide","year":"2024","journal-title":"Int. J. Hematol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1053\/j.seminhematol.2023.12.001","article-title":"Second-Line Treatment of Diffuse Large B-cell Lymphoma: Evolution of Options","volume":"60","author":"Fabbri","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1055\/a-2160-5320","article-title":"T-Zell-rekrutierende Immuntherapien des B-Zell-Lymphoms\u2014Bald in allen Therapielinien?","volume":"149","author":"Subklewe","year":"2024","journal-title":"Dtsch. Med. Wochenschr."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e4","DOI":"10.4110\/in.2022.22.e4","article-title":"Development of Bispecific Antibody for Cancer Immunotherapy: Focus on T Cell Engaging Antibody","volume":"22","author":"Moon","year":"2022","journal-title":"Immune Netw."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.3324\/haematol.2024.285255","article-title":"Sequencing of Cellular Therapy and Bispecific Antibodies for the Management of Diffuse Large B-Cell Lymphoma","volume":"109","author":"Melody","year":"2024","journal-title":"Haematologica"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Cosenza, M., Sacchi, S., and Pozzi, S. (2021). Cytokine Release Syndrome Associated with T-Cell-Based Therapies for Hematological Malignancies: Pathophysiology, Clinical Presentation, and Treatment. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22147652"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41408-024-00997-w","article-title":"Bispecific Antibodies and CAR-T Cells: Dueling Immunotherapies for Large B-Cell Lymphomas","volume":"14","author":"Trabolsi","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s40265-023-01930-4","article-title":"Epcoritamab: First Approval","volume":"83","author":"Frampton","year":"2023","journal-title":"Drugs"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1254\/fpj.23076","article-title":"Pharmacological Characteristics and Clinical Outcomes of Epcoritamab (Recombinant) (Epkinly\u00ae Subcutaneous Injection) for Malignant Lymphoma","volume":"159","author":"Takaura","year":"2024","journal-title":"Folia Pharmacol. Jpn."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1093\/jjco\/hyad186","article-title":"Recent Advances and Future Perspectives of T-Cell Engagers in Lymphoid Malignancies","volume":"54","author":"Shirouchi","year":"2024","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_18","first-page":"1483","article-title":"New Bispecific Antibodies in Diffuse Large B-Cell Lymphoma","volume":"110","author":"Minson","year":"2025","journal-title":"Haematologica"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in Relapsed\/Refractory Large B-Cell Lymphoma: 2-Year Follow-up from the Pivotal EPCORE NHL-1 Trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1182\/blood.2024026830","article-title":"Epcoritamab plus GemOx in Transplant-Ineligible Relapsed\/Refractory DLBCL: Results from the EPCORE NHL-2 Trial","volume":"145","author":"Brody","year":"2025","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a Novel, Bivalent CD20-Targeting T-Cell\u2013Engaging Bispecific Antibody, Induces Durable Complete Remissions in Relapsed or Refractory B-Cell Lymphoma: A Phase I Trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","article-title":"Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"387","author":"Dickinson","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1016\/S0140-6736(24)01774-4","article-title":"Glofitamab plus Gemcitabine and Oxaliplatin (GemOx) versus Rituximab-GemOx for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (STARGLO): A Global Phase 3, Randomised, Open-Label Trial","volume":"404","author":"Abramson","year":"2024","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1182\/bloodadvances.2023011130","article-title":"Blinatumomab Consolidation Post\u2013Autologous Stem Cell Transplantation in Patients with Diffuse Large B-Cell Lymphoma","volume":"8","author":"Ghobadi","year":"2024","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1182\/blood-2015-06-651380","article-title":"Phase 2 Study of the Bispecific T-Cell Engager (BiTE) Antibody Blinatumomab in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"127","author":"Viardot","year":"2016","journal-title":"Blood"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"6822","DOI":"10.1038\/s41467-024-51264-2","article-title":"Blinatumomab after R-CHOP Bridging Therapy for Patients with Richter Transformation: A Phase 2 Multicentre Trial","volume":"15","author":"Ysebaert","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.clml.2023.12.005","article-title":"Mosunetuzumab Safety Profile in Patients with Relapsed\/Refractory B-Cell Non-Hodgkin Lymphoma: Clinical Management Experience from a Pivotal Phase I\/II Trial","volume":"24","author":"Matasar","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-Agent Mosunetuzumab Shows Durable Complete Responses in Patients with Relapsed or Refractory B-Cell Lymphomas: Phase I Dose-Escalation Study","volume":"40","author":"Budde","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with Polatuzumab Vedotin in Relapsed or Refractory Aggressive Large B Cell Lymphoma: A Phase 1b\/2 Trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1182\/bloodadvances.2024014907","article-title":"Mosunetuzumab plus Pola-CHP Compared with Pola-R-CHP in Previously Untreated DLBCL: Final Results from a Phase 2 Study","volume":"9","author":"Westin","year":"2025","journal-title":"Blood Adv."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/bloodadvances.2024013640","article-title":"Impact of Prior CAR T-Cell Therapy on Mosunetuzumab Efficacy in Patients with Relapsed or Refractory B-Cell Lymphomas","volume":"9","author":"Chong","year":"2025","journal-title":"Blood Adv."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.clml.2024.01.006","article-title":"Geographic and Racial Disparities in Chimeric Antigen Receptor\u2013T Cells and Bispecific Antibodies Trials Access for Diffuse Large B-Cell Lymphoma","volume":"24","author":"Shahzad","year":"2024","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.4161\/onci.22524","article-title":"How Do CARs Work?: Early Insights from Recent Clinical Studies Targeting CD19","volume":"1","author":"Davila","year":"2012","journal-title":"OncoImmunology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The Basic Principles of Chimeric Antigen Receptor Design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"(2017). First-Ever CAR T-Cell Therapy Approved in U.S. Cancer Discov., 7, OF1.","DOI":"10.1158\/2159-8290.CD-NB2017-126"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e29123","DOI":"10.1002\/pbc.29123","article-title":"Tisagenlecleucel for Treatment of Children and Young Adults with Relapsed\/Refractory B-cell Acute Lymphoblastic Leukemia","volume":"68","author":"Grupp","year":"2021","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"OF4","DOI":"10.1158\/2159-8290.CD-RW2022-004","article-title":"Tisagenlecleucel Is Safe and Effective in Relapsed\/Refractory Follicular Lymphoma","volume":"12","author":"Fowler","year":"2022","journal-title":"Cancer Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1093\/oncolo\/oyac054","article-title":"FDA Approval Summary: Axicabtagene Ciloleucel for Relapsed or Refractory Follicular Lymphoma","volume":"27","author":"Bouchkouj","year":"2022","journal-title":"Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"e3237","DOI":"10.1002\/hon.3237","article-title":"How to Integrate CD19 Specific Chimeric Antigen Receptor T Cells with Other CD19 Targeting Agents in Diffuse Large B-cell Lymphoma?","volume":"42","author":"Wang","year":"2024","journal-title":"Hematol. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s00280-023-04551-6","article-title":"Infections Occurring Following IL6 Blockade for the Management of Cytokine Release Syndrome in Onco-Hematology Patients","volume":"92","author":"Valery","year":"2023","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_42","doi-asserted-by":"crossref","unstructured":"Tumuluru, S., Godfrey, J.K., Cooper, A., Yu, J., Chen, X., MacNabb, B.W., Venkataraman, G., Zha, Y., Pelzer, B., and Song, J. (2024). Integrative Genomic Analysis Identifies Unique Immune Environments Associated with Immunotherapy Response in Diffuse Large B Cell Lymphoma. bioRxiv.","DOI":"10.1101\/2024.01.17.576100"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"101140","DOI":"10.1016\/j.blre.2023.101140","article-title":"A Paradox of Choice: Sequencing Therapy in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","volume":"63","author":"Brooks","year":"2024","journal-title":"Blood Rev."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-Cell Therapy and Prophylactic Anakinra in Relapsed or Refractory Lymphoma: Phase 2 Trial Interim Results","volume":"29","author":"Park","year":"2023","journal-title":"Nat. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1182\/blood.2023023419","article-title":"CAR T Cells vs Bispecific Antibody as Third- or Later-Line Large B-Cell Lymphoma Therapy: A Meta-Analysis","volume":"144","author":"Kim","year":"2024","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"1498","DOI":"10.1182\/blood.2024027044","article-title":"Odronextamab Monotherapy in R\/R DLBCL after Progression with CAR T-Cell Therapy: Primary Analysis of the ELM-1 Study","volume":"145","author":"Topp","year":"2025","journal-title":"Blood"},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Sousa-Pimenta, M., Martins, \u00c2., Mariz, J.M., and Berraondo, P. (2023). Response to Therapy in Richter Syndrome: A Systematic Review with Meta-Analysis of Early Clinical Trials. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1295293"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/bjh.19503","article-title":"Relapse after Glofitamab, a Novel Unmet Medical Need with High Rates of CD20 Loss","volume":"205","year":"2024","journal-title":"Br. J. Haematol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1080\/21645515.2018.1540828","article-title":"Blinatumomab, a Bispecific B-Cell and T-Cell Engaging Antibody, in the Treatment of B-Cell Malignancies","volume":"15","author":"Burt","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1182\/blood-2024-193681","article-title":"Evaluation of AZD0486, a Novel CD19xCD3 T-Cell Engager, in Relapsed\/Refractory Diffuse Large B-Cell Lymphoma in an Ongoing First-in-Human Phase 1 Study: High Complete Responses Seen in CAR-T-Naive and CAR-T-Exposed Patients","volume":"144","author":"Gaballa","year":"2024","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1158\/1078-0432.CCR-22-3667","article-title":"Dissecting the Mechanisms Underlying the Cytokine Release Syndrome (CRS) Mediated by T-Cell Bispecific Antibodies","volume":"29","author":"Steinhoff","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"3681","DOI":"10.1182\/blood.2021014611","article-title":"T-Cell\u2013Redirecting Bispecific Antibodies in Multiple Myeloma: A Revolution?","volume":"139","author":"Moreau","year":"2022","journal-title":"Blood"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe Cytokine Release Syndrome Is Associated with Hematologic Toxicity Following CD19 CAR T-Cell Therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e327","DOI":"10.1016\/S2352-3026(22)00072-2","article-title":"Odronextamab, a Human CD20\u00d7CD3 Bispecific Antibody in Patients with CD20-Positive B-Cell Malignancies (ELM-1): Results from the Relapsed or Refractory Non-Hodgkin Lymphoma Cohort in a Single-Arm, Multicentre, Phase 1 Trial","volume":"9","author":"Bannerji","year":"2022","journal-title":"Lancet Haematol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"5713","DOI":"10.1182\/bloodadvances.2022009066","article-title":"The Race Is on: Bispecifics vs CAR T Cells in B-Cell Lymphoma","volume":"7","author":"Gurumurthi","year":"2023","journal-title":"Blood Adv."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and Efficacy of Mosunetuzumab, a Bispecific Antibody, in Patients with Relapsed or Refractory Follicular Lymphoma: A Single-Arm, Multicentre, Phase 2 Study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1038\/s41591-024-02986-9","article-title":"Lisocabtagene Maraleucel in Follicular Lymphoma: The Phase 2 TRANSCEND FL Study","volume":"30","author":"Morschhauser","year":"2024","journal-title":"Nat. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"999","DOI":"10.3324\/haematol.2024.286257","article-title":"Dexamethasone Is Associated with Reduced Frequency and Intensity of Cytokine Release Syndrome Compared with Alternative Corticosteroid Regimens as Premedication for Glofitamab in Patients with Relapsed\/Refractory Large B-Cell Lymphoma","volume":"110","author":"Falchi","year":"2024","journal-title":"Haematologica"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"4643","DOI":"10.1111\/cas.15996","article-title":"Subcutaneous Epcoritamab Monotherapy in Japanese Adults with Relapsed\/Refractory Diffuse Large B-cell Lymphoma","volume":"114","author":"Izutsu","year":"2023","journal-title":"Cancer Sci."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a Novel, Subcutaneous CD3xCD20 Bispecific T-Cell\u2013Engaging Antibody, in Relapsed or Refractory Large B-Cell Lymphoma: Dose Expansion in a Phase I\/II Trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1182\/blood-2022-158406","article-title":"Odronextamab in Patients with Relapsed\/Refractory (R\/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2","volume":"140","author":"Kim","year":"2022","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-Cell-Engaging Bispecific Antibodies in Cancer","volume":"402","author":"Zweegman","year":"2023","journal-title":"Lancet"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/PPO.0000000000000507","article-title":"Neurotoxicity Biology and Management","volume":"27","author":"Danish","year":"2021","journal-title":"Cancer J."},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Omer, M.H., Shafqat, A., Ahmad, O., Alkattan, K., Yaqinuddin, A., and Damlaj, M. (2023). Bispecific Antibodies in Hematological Malignancies: A Scoping Review. Cancers, 15.","DOI":"10.3390\/cancers15184550"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"545","DOI":"10.2147\/OTT.S465679","article-title":"Nephrotoxicity in Bispecific Antibodies Recipients: Focus on T-Cell-Engaging Bispecific Antibodies","volume":"17","author":"Wen","year":"2024","journal-title":"OncoTargets Ther."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Uckun, F.M., Lin, T.L., Mims, A.S., Patel, P., Lee, C., Shahidzadeh, A., Shami, P.J., Cull, E., Cogle, C.R., and Watts, J. (2021). A Clinical Phase 1B Study of the CD3xCD123 Bispecific Antibody APVO436 in Patients with Relapsed\/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome. Cancers, 13.","DOI":"10.3390\/cancers13164113"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/14712598.2024.2351995","article-title":"Bispecific Antibodies Targeting CD20xCD3 in Immunotherapy for Adult B-Cell Lymphoma: Insights from the 65th American Society of Hematology 2023 Annual Meeting","volume":"24","author":"Sun","year":"2024","journal-title":"Expert Opin. Biol. Ther."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5534\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:24:18Z","timestamp":1760034258000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/15\/5534"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,6]]},"references-count":67,"journal-issue":{"issue":"15","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14155534"],"URL":"https:\/\/doi.org\/10.3390\/jcm14155534","relation":{},"ISSN":["2077-0383"],"issn-type":[{"type":"electronic","value":"2077-0383"}],"subject":[],"published":{"date-parts":[[2025,8,6]]}}}